felbamate 400 MG Oral Tablet

INDICATIONS AND USAGE Felbamate tablets, USP are not indicated as a first line antiepileptic treatment (see WARNINGS ). Felbamate tablets are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, Felbamate tablets can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.

Alvogen Inc.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] off label use` `[4] disease progression` `[5] fatigue` `[6] vomiting` `[7] diarrhoea` `[8] thrombocytopenia` `[9] pyrexia` `[10] anaemia`

4 years ago

OVAL WHITE MYLAN FE 400

HOW SUPPLIED Felbamate Tablets, USP contain 400 mg or 600 mg of felbamate, USP. The 400 mg tablet is white to off-white, modified capsule shaped, functionally scored, debossed with MYLAN on one side of the tablet and FE on the left of the score and 400 on the right of the score on the other side of the tablet. They are available as follows: NDC 47781-550-01 bottles of 100 tablets The 600 mg tablet is white to off-white, modified capsule shaped, functionally scored, debossed with MYLAN on one side of the tablet and FE on the left of the score and 600 on the right of the score on the other side of the tablet. They are available as follows: NDC 47781-551-01 bottles of 100 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. PHARMACIST: Dispense a Medication Guide with each prescription. To report SUSPECTED ADVERSE REACTIONS, contact Alvogen, Inc. at 1-866-770-3024 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . PI550-01 Rev. 11/2016

More pills like OVAL MYLAN FE 400

Related Pills

felbamate 600 MG Oral Tablet

Alvogen Inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site